# ALKALOID – Operating Results for the January – September 2026 period > ALKALOID – Operating Results for the January – September 2026 period — Alkaloid AD Skopje Source: https://alkaloid.com.mk/alkaloid-operating-results-for-the-january-september-2026-period Oct 29, 2026 ## **ALKALOID posts** **record** **consolidated sales of EUR 263 million, invests EUR 17.3 million and hires 60 new employees in the country in the January – September 2026 period** **Sales revenue** According to the stand-alone Income Statement, in the January – September 2026 period sales reached MKD 10,358,253,210, which is 2% higher compared to the same period last year. Total consolidated sales reached MKD 16,205,440,429, which is 7% higher compared to the same period last year. **Sales by region** Consolidated sales on the domestic market increased by 13% compared to last year. As a proven partner of public healthcare, the company actively participates in providing the most modern rare and specific therapies through representation of products from globally renowned pharmaceutical manufacturers, providing significant support to the national healthcare system. Although the profitability of these programs is limited, they significantly increase the share of the domestic market in total consolidated sales. Of total consolidated sales, 37% were realized on the domestic market, while 63% were realized on foreign markets. By region, 28% were realized in the countries of South-East Europe, 18% in the countries of Eastern Europe (CIS, UKR...), and 17% in the countries of Western Europe (EU and EFTA). The highest growth in export markets compared to last year was recorded in Kazakhstan, where sales increased 3.3-fold, as well as in Switzerland, where sales increased 2.6-fold. This is followed by Jordan (growth of 94%), Greece (growth of 89%), the United Kingdom (growth of 83%), Cyprus (growth of 74%), Lithuania (growth of 65%), Mongolia (growth of 30%), Armenia (growth of 16%), Georgia (growth of 14%), Germany (growth of 13%), etc. **Sales by product group** By product groups, in the structure of total consolidated sales, the products from the Pharmaceuticals segment account for the largest share, i.e. 92%. Within this segment, antibiotics account for 19%, OTC products for 18%, neurological products for 14%, cardiovascular products for 12% of total consolidated sales, etc. The Chemistry, Cosmetics and Botanicals segment participates with 8% of total consolidated sales, more precisely Chemistry with 2%, Cosmetics with 5%, and Botanicals with 1%. **Investments** Total consolidated investments in property, plant and equipment in the period January – September 2026 amount to MKD 1,067,280 thousand, representing an increase of 34% compared to the same period of the previous year. Part of the total investments relate to investments realized through the related company ALKALOID ENERGETIKA DOOEL, aimed at the construction and development of photovoltaic capacities for electricity generation from renewable sources, which started trial operation in July 2026. **Operating results** Stand-alone earnings before financial expenses, taxes and depreciation and amortization (EBITDA), in the amount of MKD 2,724,714,506, recorded an increase of around 7%, while stand-alone net profit amounted to MKD 1,636,713,332 and increased by 7%. Consolidated earnings before financial expenses, taxes and depreciation and amortization (EBITDA) reached MKD 2,990,429,419 and recorded a growth of 8%, while consolidated net profit in the amount of MKD 1,544,111,223 increased by 4%. **Employees** In the period January – September 2026, ALKALOID AD Skopje hired 60 new employees in the Republic of North Macedonia. The average net salary per employee in the company in September 2026 was MKD 68,950. By decision of the Management Board of ALKALOID AD Skopje, in 2026 a vacation allowance in the amount of MKD 47,000 net was approved and paid to the company's employees. The ALKALOID Group employs 3,019 people, of which 2,201 are in the country and 818 are employed in the capital-related companies abroad. **Shares** The shares of ALKALOID AD Skopje have been listed on the official market of the Macedonian Stock Exchange since 2002 and are among the most traded and most liquid shares on the Exchange. In the January – September 2026 period, the share price ranged from MKD 21,745.00 to MKD 27,300.00, with an average of MKD 24,398.08 per share. On 30.09.2026, ALKALOID AD Skopje shares were held by 6,657 shareholders (individuals and legal entities), while the company’s market capitalization amounted to MKD 31.64 billion. On 30 March 2026, at the Annual Shareholders’ Assembly, the calculation and payment of gross dividend for 2025 in the amount of MKD 1,030,574 thousand was approved. In accordance with the dividend calendar, in May 2026 the company started paying dividend in the amount of MKD 720 gross, i.e. MKD 648 net for one share. The dividend per share for 2025 is 14.3% higher than the dividend paid per share for 2024. **2026 Business Plan** The 2026 Business Plan, adopted by the Management Board of ALKALOID AD Skopje at its December 29th, 2025 meeting, anticipates investment of around 8% of the consolidated revenue in tangible and intangible assets, growth in consolidated sales of 7% compared to the actual sales in 2025, and growth in consolidated profit of 7% in comparison to 2025. The results achieved in the first nine months of 2026 are in line with the planned dynamics of implementation of the business plan. In the next period, cumulative placements on the domestic and foreign markets are expected to exceed last year’s achievements and to reach the planned targets. The 2026 Business Plan is based on the expectations, forecasts and opportunities on the existing and new markets and products available to the Company at the time of drafting the plan. Circumstances and events in 2026 may vary from those taken into account in the Business Plan and so may actual results. **Expectations for the upcoming period** The trend of operating within challenging economic conditions, which were present in recent years, continues in 2026 as well. Dominant challenges were inflation and the increase in interest rates, as well as pressure on consumers’ purchasing power, which affects consumption and demand dynamics in certain markets, while uncertainty remains pronounced. The company is exposed to interest rate risk mainly on the basis of short-term and long-term loans, whereby this is continuously monitored and managed through direct negotiations with banks, without significant oscillations in interest rates. At the same time, global security crises, including the escalation of the conflict related to Iran, further complicate the economic environment and predictability. These developments have a significant impact on global energy markets, causing increases and heightened volatility in energy prices, which creates additional inflationary pressures and difficulties in supply chains, as well as risks related to the availability of certain raw materials and other materials. In addition, the potential risk of an escalation of global trade tensions may trigger further increases in raw material prices and lead to higher operating costs. We carefully monitor developments and take appropriate measures to mitigate these potential effects. We expect in 2026 to continue along the path of continuous growth based on the opportunities from our current investments in new manufacturing capacities and equipment, and from investments in research and development projects, thus creating a competitive portfolio and opportunities for market expansion. To achieve these goals, we will continue hiring in the country as well as in foreign markets, while continuously investing in raising and improving the level of knowledge and skills of our employees and in building talents. Oct 29, 2026[ALKALOID – Operating Results for the January – September 2026 period](https://alkaloid.com.mk/alkaloid-operating-results-for-the-january-september-2026-period) * * * Oct 28, 2026[ALKALOID BECOMES THE FIRST COMPANY IN MACEDONIA TO RECEIVE THE PRESTIGIOUS TOP EMPLOYER 2026 CERTIFICATION](https://alkaloid.com.mk/alkaloid-top-employer-2026) * * * Oct 8, 2026[ALKALOID MARKS ITS 23RD PARTICIPATION IN CPHI, THE WORLD’S LEADING PHARMACEUTICAL EVENT](https://alkaloid.com.mk/alkaloid-marks-its-23-rd-participation-in-cphi-the-world-s-leading-pharmaceutical-event) * * * Sep 22, 2026[MUKAETOV AT THE 25TH MACEDONIAN STOCK EXCHANGE CONFERENCE: SMALL MARKET, BIG OPPORTUNITY](https://alkaloid.com.mk/mukaetov-at-the-25th-macedonian-stock-exchange-conference) * * * Sep 21, 2026[FROM ATOP A FACTORY CHIMNEY TO AN ART INSTALLATION: THE STORY OF ALKALOID’S HISTORIC SIGN](https://alkaloid.com.mk/from-atop-a-factory-chimney-to-an-art-installation-the-story-of-alkaloid-s-historic-sign) * * *